What is the difference between cagrilintide and CagriSema
Whilst their primary indications relate to glycaemic control and weight management, emerging evidence suggests potential cardiovascular benefits that extend beyond these core therapeutic areas
Certification ensures that Semaglutide is produced consistently and safely, providing confidence to healthcare providers and patients
When gut health, metabolism, and medical therapy work together, results are not only more effectivebut more sustainable
The majority of these therapies aim to replicate or inhibit the effects of various gut hormones such as GLP-1, GIP, amylin, and glucagon [27, 28]
In 2020 the FDA approved Sogroya (somapacitan-beco) a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency